Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion Inc (NQ: BMEA )

11.22 +0.39 (+3.65%)
Streaming Delayed Price Updated: 1:55 PM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 334,426
Open 10.79
Bid (Size) 11.20 (3)
Ask (Size) 11.25 (10)
Prev. Close 10.83
Today's Range 10.72 - 11.39
52wk Range 8.125 - 43.69
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
BMEA Stock Earnings: Biomea Fusion Misses EPS for Q4 2023
BMEA stock results show that Biomea Fusion missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace

Performance

YTD
-23.48%
-23.48%
1 Month
-26.68%
-26.68%
3 Month
-23.06%
-23.06%
6 Month
+6.50%
+6.50%
1 Year
-62.58%
-62.58%

More News

Read More
Recap: Biomea Fusion Q4 Earnings
Via Benzinga
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
What's Going On With Biomea Fusion Stock?
Via Benzinga
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
Via InvestorPlace
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
Via InvestorPlace
3 Speculative Stocks That Could Make Your February Unforgettable
Via InvestorPlace
3 Long-Term Stocks to Buy on the Dip: February 2024
Via InvestorPlace
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Topics Stocks
Exposures US Equities
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Via Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Jim Cramer Says Move On From This Energy Stock: 'It's Moved Too Much'
Via Benzinga
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Why bluebird bio Shares Are Trading Higher? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Coinbase, Riot Platforms, Marathon Digital And Other Big Stocks Moving Lower On Monday
Via Benzinga
Topics Stocks
Exposures US Equities
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
From Biomea Fusion, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Green Giant Shares Are Trading Lower By Around 37%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.